AUTHORS
Ibrahim Aldoss, MD, Carl T. Shultz2, Bradley D. Hunter3, David Swoboda, MD4, Pau Montesinos, MD5, Sarit E. Assouline, MDCM, MSc, FRCPC6, Brian Parkin, MD7, Karla Malloy, MD, PhD8, Enoch Cobbina, PhD, MS9, Jingshan Zhang10, Angela R. Smith, MD11, Shaun Fleming, MBBS (Hons), PhD12, Carolyn S. Grove, MBBS, PhD, FRACP, FRCPA13, Andre C. Schuh14, Moaath Mustafa Ali, MD, MPH15, David C. Taussig, PhD,MRCP,FRCPath16, Eytan M Stein I, MD17, John F. DiPersio, MD18
AFFILIATIONS
1 City of Hope National Medical Center, Duarte, California, United States
2 Transplant and Cellular Therapy/Hematologic Malignancies, Department of Medical Oncology, West Virginia University, Morgantown, West Virginia, United States
3 Intermountain Health, Salt Lake City, Utah, United States
4 Tampa General Hospital Cancer Institute, Tampa, Florida, United States
5 Hospital Universitari i Politècnic La Fe, Valencia, Spain
6 Division of Hematology, Department of Medicine and Oncology, McGill University, Montreal, Quebec, Canada
7 AdventHealth, Orlando, Florida, United States
8 Syndax Pharmaceuticals, Inc., New York, New York, United States
9 Syndax Pharmaceuticals, Inc., New York, New York, United States
10 Syndax Pharmaceuticals, Inc., New York, New York, United States
11 Syndax Pharmaceuticals, Inc., New York, New York, United States
12 The Alfred Hospital, and Monash University, Melbourne, Victoria, Australia
13 Sir Charles Gairdner Hospital, PathWest, and The University of Western Australia, Nedlands, WA, Australia
14 Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada
15 The Cleveland Clinic, Cleveland, Ohio, United States
16 The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Washington University School of Medicine, St. Louis, Missouri, United States
ABSTRACT
Background: Newly diagnosed (ND) acute myeloid leukemia (AML) harboring an NPM1 mutation (NPM1m) in patients (pts) ≥ 65 years (y) or with adverse mutations, as well as AML with rearrangements in KMT2A and NUP98 (KMT2Ar and NUP98r), are associated with high relapse rates, persistent measurable residual disease (MRD), and short overall survival. These genomic alterations block hematopoietic differentiation and drive leukemogenesis by sustaining the menin-KMT2A interaction. Revumenib, a first-in-class, oral, potent, and selective inhibitor of the menin-KMT2A interaction, is used for the treatment of relapsed/refractory (R/R) AML with NPM1m or R/R acute leukemias harboring a KMT2A translocation in adult and pediatric pts 1 y and older. Treatment response could be improved by adding revumenib to intensive chemotherapy (IC) regimens to further decrease leukemic cell proliferation in ND pts. This updated analysis reports efficacy, pharmacokinetic (PK), and safety data for revumenib + IC in ND AML pts in the SNDX-5613-0708 study.
Methods: SNDX-5613-0708 (NCT06226571) is a global, multicenter, open-label, dose-escalation and -expansion study enrolling pts 18–75 years with ND AML with NPM1m, KMT2Ar, or NUP98r eligible for IC. Two dose levels (DL) of revumenib were evaluated (DL1: 220 mg or 110 mg + strong CYP3A4 inhibitor [CYP3A4i]; DL2: 270 mg or 160 mg + strong CYP3A4i) in combination with cytarabine + daunorubicin/idarubicin. Pts achieving complete remission (CR) or CR with incomplete hematologic recovery received consolidation therapy (revumenib + high-dose cytarabine), then hematopoietic stem cell transplant (HSCT) ± revumenib maintenance until disease progression or toxicity. Endpoints relevant to this analysis are overall response rate (ORR), composite CR (CRc) rate, MRD-negative (MRD−) CR rate (assessed locally; exploratory, with more sensitive methods used for DL2), PK parameters (secondary); dose-limiting toxicities and safety (primary).
Results: As of 30Nov2025, 15 pts were treated at DL1 and 20 at DL2. Pts in DL1 were a median age of 43.0 y vs 57.5 y in DL2. KMT2Ar was detected in 13/15 (87%) pts in DL1 and 8/20 (40%) in DL2; NPM1m was detected in 2/15 (13%) pts in DL1 and 12/20 (60%) in DL2. Median (range) number of revumenib cycles received was 3 (1–8) in DL1 and 2 (1–5) in DL2.
In the response-evaluable population, both the ORR and CRc rate were 100% (15/15) in DL1 and 95.0% (19/20) in DL2; CR rate was 80.0% (12/15) and 75.0% (15/20), respectively. MRD− CR was achieved in 100% (9/9) of tested pts in DL1 and 78.6% (11/14) in DL2. In DL1 and DL2, respectively, 9/15 (60%) pts and 2/20 (10%) pts proceeded to HSCT (possibly due to more pts with KMT2Ar in DL1 and shorter follow-up in DL2). All pts who proceeded to HSCT had KMT2Ar AML. Of these, 6/9 (66.7%) pts in DL1 and none in DL2 resumed revumenib maintenance monotherapy after HSCT at the last tolerated dose; 3/6 (50.0%) were continuing treatment at data cutoff.
In the safety population, 14/15 (93%) pts in DL1 and 20/20 (100%) in DL2 experienced a treatment-emergent adverse event (grade ≥3: 13 pts [87%, DL1]; 19 [95%, DL2]). Any-grade QTcF prolongation occurred in 3 (20%) pts in DL1 and 5 (25%) in DL2; 2 (13%) and 2 (10%) were grade 3 (none grade 4). One pt in DL2 experienced grade 3 differentiation syndrome.
As of 29May2026, the maximum concentration (Cmax) of revumenib during induction was 2070 ng/mL in DL1 and 2810 ng/mL in DL2 (NPM1m, 2740; KMT2Ar, 2930). The average concentration (Cavg) of revumenib was 1580 ng/mL in DL1 and 2060 ng/mL in DL2 (NPM1m, 1970; KMT2Ar, 2220). The area under the curve (AUC) was 9500 ng∙h/mL in DL1 and 12300 ng∙h/mL in DL2 (NPM1m, 11800; KMT2Ar, 13300).
Conclusions: Deep clinical responses were observed across DLs, including high rates of MRD− CR. The safety profile remained consistent with prior studies, with no new safety signals identified. PK profiles were consistent with those in the monotherapy study, indicating that IC agents used had no clinically relevant impact on exposure to revumenib. Revumenib exposures were similar between NPM1m and KMT2Ar pts, suggesting mutation type did not impact PK. These data demonstrate robust clinical activity in ND NPM1m and KMT2Ar AML and support the ongoing phase 3 REVEAL-ND trial (NCT07211958). Additional data from the expansion cohort will be presented.
DISCLOSURES
Ibrahim Aldoss, MD: Amgen - Honoraria; Pfizer - Honoraria; Allotera - Research Funding; Jazz Pharmaceuticals - Research Funding; Novartis - Research Funding; MacroGenics - Research Funding; AbbVie - Research Funding; Autolus - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Menarini Stemline - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Syndax Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Acentage - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Adaptive - Consultancy (Includes expert testimony); Allotera - Consultancy (Includes expert testimony)